Earnings Scheduled For March 8, 2023
Companies Reporting Before The Bell
• Daktronics (NASDAQ:DAKT) is expected to report quarterly earnings at $0.00 per share on revenue of $164.68 million.
Opthea’s Phase 2B Results Of OPT-302, Anti-VEGF-C/-D “Trap” Agent Administered In Combination With Lucentis (Ranibizumab) For Wet Age-Related Macular Degeneration Have Been Published In Ophthalmology, Journal Of The American Academy Ophthalmology
The prospective, randomized, controlled Phase 2b trial of 366 treatment-naïve patients with wet AMD, demonstrated that monthly intravitreal administration of 2.0 mg OPT-302 with ranibizumab standard of care, met the
Earnings Scheduled For November 8, 2022
Companies Reporting Before The Bell
• Adtran (NASDAQ:ADTN) is likely to report quarterly earnings at $0.18 per share on revenue of $330.39 million.
Citigroup Maintains Buy on Opthea, Lowers Price Target to $44
Citigroup analyst Yigal Nochomovitz maintains Opthea (NASDAQ:OPT) with a Buy and lowers the price target from $45 to $44.
Earnings Scheduled For August 9, 2022
Companies Reporting Before The Bell
• Cognition Therapeutics (NASDAQ:CGTX) is estimated to report earnings for its second quarter.
Earnings Scheduled For May 10, 2022
Companies Reporting Before The Bell
• The Middleby (NASDAQ:MIDD) is expected to report quarterly earnings at $2.10 per share on revenue of $935.99 million.
Stocks That Hit 52-Week Lows On Wednesday
During Wednesday's session, 35 companies made new 52-week lows.
Earnings Scheduled For March 8, 2022
Companies Reporting Before The Bell
• Babcock & Wilcox (NYSE:BW) is likely to report quarterly earnings at $0.10 per share on revenue of $196.62 million.
